We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators
News

Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators

Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators
News

Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Phase I Clinical Trials of Cancer Drug ETS2101 Approved by Regulators"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

e-Therapeutics plc has announced that regulatory agencies in the UK and the US have approved plans for phase I trials of the Company’s anti-cancer drug ETS2101 and that enrolment of patients into trials in these two countries will begin shortly.

A phase I trial in the UK will recruit patients with a variety of solid tumours, while a US investigator-led trial will enrol patients with primary or secondary brain cancers.

Further details of each trial will be provided when its first patient is treated.

Professor Malcolm Young, CEO of e-Therapeutics, said: “We remain on track to report the first data from cancer trials with ETS2101 and to advance three further drugs into the clinic by the end of this year.”

e-Therapeutics’ latest expectations for its other products are that ETX1153c (for C. difficile infection) will start phase I in Q2 or Q3, that ETS6103 (for major depressive disorder) will enter phase IIb in Q3 and that ETX1153a (for MRSA infection) will start phase I in Q4.

Advertisement